We provide a Point-Of-Care, cost efficient Tissue Engineering approach to regenerative, patient-tailored precision medicine. We focus on clinical indications performed in the operating theater by providing patient accessibility. At the heart of this revolutionary approach is a proprietary bio-processing technology:
"Sound Induced Morphogenesis " - SIMmimiX biotherapeutics aims to deliver the next generation biofabrication technology, that will enable tissue manufacturing for therapeutic and diagnostic purposes. We will make this vision a reality by providing an ultra-fast biomanufacturing technology capable of creating Point-Of-Care patient specific biological tissue equivalents for regenerative, personalized and precision medicine.
mimiX biotherapeutics’ technology has already demonstrated – with strong scientific evidence – that it offers tissue engineering strategies to overcome today’s obstacles, including the creation of dense networks of micro vascularization. Our technology is a game changer for regenerative medicine and diagnostics.
During the last few years, remarkable progress has been made in gene and cell therapy. Positive proof-of-principle results have been obtained for several diseases, such as adrenoleukodystrophy, hemophilia IX, β-thalassemia, malignant glioblastoma, leukemia and other types of cancer. Thus, it is expected that several new gene therapy products will enter the clinical arena in the not-so-distant future. In cell therapy, iPS cell technology has opened huge possibilities for cell therapy and regenerative medicine. There are still significant challenges in gene and cell therapy before these new approaches can enter main stream medicine. Significant safety issues have been reported in some trials and the need for better vectors, delivery techniques and treatment genes are widely recognized. With years of experience in providing high-quality products and services in the field of biopharmaceuticals for customers all over the world, scientists in Creative Biolabs will be more focused on developing first class product and technology to meet the need of stem cell therapy development.
3DBio Therapeutics is a biologics and bioprinting company with a focus on regenerative medicine that precision manufactures living tissues to allow replacement of each individual patient’s parts with tissues designed and created specifically for them.
We are a tech start-up based in Stockholm, Sweden. Akira Science provides pliable 3D-printed scaffolds for soft tissue engineering. Our customized scaffolds are the result of the combined expertise in degradable polymer synthesis, mechanical simulation and cell-material interaction.
Today, there is a solid clinical standard for treating joint disease: the total joint replacement. Yet, while the surgical devices and techniques used to implant them have been largely perfected, today’s standard replacement joints don’t last forever. The limited lifespan of common replacement joints limits their use to patients aged 55 or older. This leaves patients between ages 18 and 55 suffering from cartilage damage, traumatic injury, or early stage cartilage loss with limited treatment options.
Our company, Nanochon, is developing an implant that is designed to not only replace lost and damaged cartilage, but also to encourage new tissue growth. Using 3-D printing and novel material, the Nanochon implant is a sturdy medical advancement that is both an orthopedic load bearing implant as well a tissue growth scaffold. The Nanochon implant has the potential to deliver faster and more successful recoveries for patients, while reducing costs to health providers, payers, and patients. Nanochon’s aim is to set a new clinical standard for cartilage restoration.
Today, Samsara cells and tissues are enabling cutting edge research in the study of human biology and disease. In the hands of our partners and customers, our cells are contributing to the advancement of new tissue models, helping researchers identify promising new drugs that may treat life-threatening diseases, and breaking new ground in regenerative medicine.
The Foundation for Research and Science Development was established in 2009 and has the status of a Scientific Unit entered into the POLON MNiSW (Ministry of Science and Higher Education) system. The organization deals mainly with educational and research activities in the field of medical and biochemical sciences. It was created out of passion and the will to change the reality that surrounds us. The inspiration for establishing the Foundation was and is the scientific activity of Michał Wszoła MD, PhD., surgeon, transplantologist and, most of all, a dedicated doctor.
Founded in 2016, Qrons is a publicly traded, preclinical biotechnology company, developing advanced cell-based solutions to combat neurological injuries. While we are laser-focused on traumatic brain injury (TBI), our technology could potentially treat a wide range of neurodegenerative diseases.
BIOLIFE4D is a pioneering biotech company laser focused on leveraging advances in life sciences and tissue engineering to 3D bioprint a viable human heart suitable for transplant – lifesaving technology that gives patients the gift of time.
AstraZeneca established the BioVentureHub in 2014 as an open innovation ecosystem to further strengthen competitiveness and dynamism in the Scandinavian life science industry. Based on an innovative public-private partnership model and located at the heart of AstraZeneca Gothenburg, the BioVenturehub gives emerging biotech/medtech companies and academic groups from Sweden and abroad a unique opportunity to co-locate with - and tap into - the power of AstraZeneca’s world-class scientists and state-of-the-art lab facilities and infrastructure, and with each other.
SE3D.com is an EdTech startup, funded by the National Science Foundation, specializing in science education courseware and desktop 3D bioprinters for K9-14. Our unique curriculum and equipment is designed to prepare and propel the next generation of biomedical scientists, engineers and innovators.
CollPlant Biotechnologies is a regenerative medicine company focused on 3D bioprinting of tissues and organs, and the development of medical aesthetics products. CollPlant’s revolutionary products, including its BioInks, are based on its proprietary recombinant human collagen (rhCollagen) which is produced in genetically engineered tobacco plants. CollPlant recently entered a licensing deal worth $44 million plus royalties with United Therapeutics, a $4 billion company, for its BioInk technology to manufacture 3D bioprinted lungs for transplantation. In the medical aesthetics market, CollPlant is developing 3D bioprinted breast implants for regeneration of breast tissue, and a dermal filler product line for the $4.5 billion global dermal filler market. CollPlant is currently in talks for potential strategic partnerships with big pharma companies for its BioInk and medical aesthetics technologies.Collplant is a public company listed on the Tel Aviv Stock Exchange and on the OTCQX
The Institute for Bioengineering of Catalonia (IBEC) conducts excellent interdisciplinary research at the frontiers of engineering and life sciences in order to generate new knowledge by putting together fields like nanomedicine, biophysics, biotechnology, tissue engineering and the applications of health information technology.